WuXi to build manufacturing facility in U.S.

By The Science Advisory Board staff writers

May 19, 2020 -- WuXi Biologics announced it has signed a deal with Worcester Business Development to build a clinical and commercial manufacturing facility in Worcester, MA.

The 107,000-sq-ft facility is expected to be completed in 2022. The location is the first U.S. biomanufacturing facility for WuXi. According to the company, the campus will be located on a 46-acre plot and will create 150 new jobs for the local economy.

WuXi is a Hong-Kong based drug discovery and clinical and commercial manufacturing organization. It currently has over 100 projects in phase I and II clinical development and 16 in phase III development, as well as one project in commercial manufacturing.

Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia
Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support...
Florida CRO expands drug screening and manufacturing
Florida-based contract research organization (CRO) Alchem Laboratories is constructing a new building to grow its screening and chemical trail manufacturing...
Audentes plans gene therapy facility in NC
Audentes Therapeutics has announced that it plans to invest $109 million to build a new 135,00-sq-ft gene therapy manufacturing facility in Sanford,...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter